The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Compliance with ASCO 2006 recommendations for the use of "white blood cell growth factors" in advanced lung cancer (LC) or breast cancer (BC) or non-Hodgkin lymphoma (NHL): An interim analysis of French National Observational Study—The ZOHé study.
Hubert Orfeuvre
No relevant relationships to disclose
Jean-Loup Mouysset
No relevant relationships to disclose
Omar Benbrahim
No relevant relationships to disclose
Kunlun Liu
No relevant relationships to disclose
Jean-Christophe Eymard
Honoraria - Sandoz
Domitille Fernet
No relevant relationships to disclose
Camille Aubron-Olivier
No relevant relationships to disclose
Henri Hubert Roche
No relevant relationships to disclose
Philippe Solal-Celigny
Consultant or Advisory Role - Sandoz
Toledano Alain
No relevant relationships to disclose
Corinne Haioun
Consultant or Advisory Role - Amgen; Chugai Pharma; Sandoz
Honoraria - Amgen; Chugai Pharma; Sandoz